These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 18991673)
1. Modulation of cardiac metabolism during myocardial ischemia. Chagas AC; Dourado PM; Galvão Tde F Curr Pharm Des; 2008; 14(25):2563-71. PubMed ID: 18991673 [TBL] [Abstract][Full Text] [Related]
2. Role of metabolically active drugs in the management of ischemic heart disease. Schofield RS; Hill JA Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049 [TBL] [Abstract][Full Text] [Related]
3. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Lee L; Horowitz J; Frenneaux M Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367 [TBL] [Abstract][Full Text] [Related]
10. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Lee L; Campbell R; Scheuermann-Freestone M; Taylor R; Gunaruwan P; Williams L; Ashrafian H; Horowitz J; Fraser AG; Clarke K; Frenneaux M Circulation; 2005 Nov; 112(21):3280-8. PubMed ID: 16301359 [TBL] [Abstract][Full Text] [Related]
11. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy. Belardinelli R Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102 [TBL] [Abstract][Full Text] [Related]
12. Modification of myocardial substrate use as a therapy for heart failure. Abozguia K; Clarke K; Lee L; Frenneaux M Nat Clin Pract Cardiovasc Med; 2006 Sep; 3(9):490-8. PubMed ID: 16932766 [TBL] [Abstract][Full Text] [Related]
13. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228 [TBL] [Abstract][Full Text] [Related]
14. Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Scolletta S; Biagioli B Biomed Pharmacother; 2010 Mar; 64(3):203-7. PubMed ID: 19954925 [TBL] [Abstract][Full Text] [Related]
18. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure. Dalal JJ; Mishra S Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439 [TBL] [Abstract][Full Text] [Related]
19. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Lopaschuk GD Am J Cardiol; 1998 Sep; 82(5A):14K-17K. PubMed ID: 9737481 [TBL] [Abstract][Full Text] [Related]
20. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective. Wolff AA; Rotmensch HH; Stanley WC; Ferrari R Heart Fail Rev; 2002 Apr; 7(2):187-203. PubMed ID: 11988642 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]